Using detection of survivin‐expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer

Cao, Weiguo; Yang, Weiping; Li, Hao; Lou, Guying; Jiang, Jinsong; Geng, Mei; Wu, Xi; Ren, Rong; Qu, Qing; Jin, Xiaolong; Zhu, Yanbo; Jin, Yongfeng

doi:10.1002/jso.21777

Cited by 39 publications

(43 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They reported that 3‐year DFS rates in patients who were positive or negative for survivin mRNA were 53.1% and 84.3%, respectively ( P < 0.001). Furthermore, a multivariate analysis identified the status of survivin mRNA as an independent prognostic factor ( P < 0.001) 32. In a study on 55 gastric cancer patients with stages I–IV, Yie et al .…”

Section: Prognostic Impact Of Ctcmentioning

confidence: 99%

“…Recent studies reported the clinical utility of new molecular markers for RT‐PCR assays to detect CTC in the peripheral blood of patients with gastric cancer 37. Survivin has been attracting attention as a promising blood marker for CTC in gastric cancer 25, 26, 32. Survivin is a member of the inhibitor of apoptosis gene family and plays an important role in tumor progression 38.…”

Section: Detection Of Ctcmentioning

confidence: 99%

“…Cao et al 32. focused on survivin as a novel blood marker of CTC in a qRT‐PCR study on 98 gastric cancer patients with stages I–IV 32.…”

Section: Prognostic Impact Of Ctcmentioning

confidence: 99%

“…focused on survivin as a novel blood marker of CTC in a qRT‐PCR study on 98 gastric cancer patients with stages I–IV 32. They reported that 3‐year DFS rates in patients who were positive or negative for survivin mRNA were 53.1% and 84.3%, respectively ( P < 0.001).…”

Section: Prognostic Impact Of Ctcmentioning

confidence: 99%

See 3 more Smart Citations

Clinical significance of circulating tumor cells in blood from patients with gastric cancer

Arigami

Uenosono

Yanagita

et al. 2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Circulating tumor cells (CTC) have been focused on as a target for detecting occult tumors, predicting therapeutic responses and prognoses, and monitoring postoperative recurrence in the clinical management of patients with various malignancies, including gastric cancer. Recent advances in molecular diagnostic tools have contributed to high sensitivity and specificity for the detection of CTC. A conspicuous disparity exists in the incidence of CTC among studies. However, a close relationship has been reported between positivity for CTC and well‐known prognostic clinicopathological factors including depth of tumor invasion, lymph node metastasis, stage, and lymphatic and venous invasion in patients with gastric cancer. According to most studies published on the clinical impact of CTC, the presence of CTC negatively affects the prognosis of patients with gastric cancer. Moreover, the study of CTC based on a meta‐analysis demonstrated their importance as a poor prognostic indicator. In clinical management, pre‐ and post‐therapeutic monitoring of CTC using liquid biopsy may be useful for early detection of subclinical patients or disease recurrence, prediction of tumor progression, and administrative control of adjuvant chemotherapy. Although their functional properties remain unclear, molecular profiling of CTC may contribute to the development of personalized treatment that effectively inhibits tumor progression in patients with advanced gastric cancer. We herein review the clinical significance of CTC as a promising blood marker and therapeutic target in patients with gastric cancer.

show abstract

Section: Prognostic Impact Of Ctcmentioning

confidence: 99%

Section: Detection Of Ctcmentioning

confidence: 99%

“…Cao et al 32. focused on survivin as a novel blood marker of CTC in a qRT‐PCR study on 98 gastric cancer patients with stages I–IV 32.…”

Section: Prognostic Impact Of Ctcmentioning

confidence: 99%

Section: Prognostic Impact Of Ctcmentioning

confidence: 99%

See 2 more Smart Citations

Clinical significance of circulating tumor cells in blood from patients with gastric cancer

Arigami

Uenosono

Yanagita

et al. 2017

Annals of Gastroent Surgery

View full text Add to dashboard Cite

show abstract

“…Even patients who present in the most favorable condition and who undergo curative surgical resection often die of recurrent disease (Duncavage et al, 2010;Dozois et al, 2011). Although preoperative tumor staging is useful to select the appropriate therapeutic strategy for GC patients, clinical tumor staging alone cannot predict patients' prognosis (Shimada et al, 2010;Cao et al, 2011;Feng et al, 2011). It has been reported that some immune-related biomarkers for diagnosis/prognosis and therapy monitoring of GC patients (Aburatani 2005;Tan et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Elevated Circulating CD19⁺Lymphocytes Predict Survival Advantage in Patients with Gastric Cancer

Qian¹,

Yu²,

Ling³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis

et al. 2014

View full text Add to dashboard Cite

The prognostic significance of circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) in patients with gastric cancer (GC) is controversial. The aims of our meta-analysis are to assess its correlation with clinicopathological characteristics and prognostic significance in GC. PubMed, Embase, the Cochrane database, the Science citation index, the CNKI database and the references of relevant studies were systematically searched (up to November, 2013). Using the random-effect model, the meta-analysis was completed with odds ratio (OR), risk ratio, hazard ratio (HR) and 95% confidence intervals (CI) as effect values. Twenty-six studies containing 2,566 patients with GC were analyzed. The overall analysis showed that the incidence difference of tumor cells (CTCs/DTCs) was significant when comparing the stage I/II group to the stage III/IV group (OR 5 0.36, CI [0.23, 0.56 Gastric cancer (GC) is the fourth most frequently diagnosed cancer and second leading cause of cancer death worldwide.1 Curative resection remains common and the main treatment for GC. Even though the clinical prognosis for GC has been improved by the development of surgery and adjuvant chemoradiotherapy, 2 the long-term survival of advanced GC patients is highly unsatisfactory and hindered by recurrence and distant metastasis.In recent years, extensive studies have demonstrated that tumor cells in bone marrow (BM, i.e., disseminated tumor cells [DTCs]) and peripheral blood (PB, i.e., circulating tumor cells [CTCs]), 3 which were first reported by Ashworth in 1869, 4 are related to tumor metastasis and relapse. Currently, highly sensitive and specific diagnostic methods have been developed and used for tumor cell detection, including reverse-transcriptase polymerase chain reaction (RT-PCR), immunocytochemistry (ICC), flow cytometry (FCM), and the CellSearch system that targets either tumor-associated mRNA or cytokeratin (CK) isozymes. 5 Many researchers using these

show abstract

Using detection of survivin‐expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer

Abstract: The detection of CTCs expressing survivin mRNA could be a good clinical biomarker used to predict the prognosis of patients with curatively resected gastric cancer.

Cited by 39 publications

References 34 publications

Clinical significance of circulating tumor cells in blood from patients with gastric cancer

Clinical significance of circulating tumor cells in blood from patients with gastric cancer

Elevated Circulating CD19⁺Lymphocytes Predict Survival Advantage in Patients with Gastric Cancer

Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis

Contact Info

Product

Resources

About

Using detection of survivin‐expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer

Abstract: The detection of CTCs expressing survivin mRNA could be a good clinical biomarker used to predict the prognosis of patients with curatively resected gastric cancer.

Cited by 39 publications

References 34 publications

Clinical significance of circulating tumor cells in blood from patients with gastric cancer

Clinical significance of circulating tumor cells in blood from patients with gastric cancer

Elevated Circulating CD19+Lymphocytes Predict Survival Advantage in Patients with Gastric Cancer

Clinicopathological and prognostic significance of circulating tumor cells in patients with gastric cancer: A meta-analysis

Contact Info

Product

Resources

About

Elevated Circulating CD19⁺Lymphocytes Predict Survival Advantage in Patients with Gastric Cancer